VERU INC (VERU) Stock News

USA - NASDAQ:VERU - US92536C2026 - Common Stock

3.47 USD

-0.1 (-2.8%)

Last: 9/19/2025, 8:00:02 PM

3.62 USD

+0.15 (+4.32%)

After Hours: 9/19/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

VERU Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Zacks Investment Research - Mentions: REGN LLY SRRK

Veru Announces Novel Modified-Release Oral Formulation for Enobosarm

a month ago - By: Veru Inc.

Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress

a month ago - By: Benzinga - Mentions: BKV IMCC VALN PRTS ...

Earnings Scheduled For August 12, 2025

a month ago - By: Benzinga

A Look Ahead: Veru's Earnings Forecast

2 months ago - By: Veru Inc.

Veru Announces Reverse Stock Split

a month ago - By: Veru Inc.

Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study

2 months ago - By: Veru Inc.

Veru to Report Fiscal 2025 Third Quarter Financial Results on August 12th

2 months ago - By: Veru Inc.

Veru to Participate in the 2025 BTIG Virtual Biotech Conference

3 months ago - By: Veru Inc.

Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation

3 months ago - By: Veru Inc.

Veru to Participate in the Virtual BTIG Obesity Health Forum

4 months ago - By: Veru Inc.

Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone

5 months ago - By: Veru Inc.

Veru Participates in a Virtual Investor KOL Connect Segment

5 months ago - By: Veru Inc.

Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

5 months ago - By: Veru Inc.

Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8

5 months ago - By: Veru Inc.

Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit

6 months ago - By: Veru Inc.

Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

7 months ago - By: Veru Inc.

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

8 months ago - By: Veru Inc.

Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

8 months ago - By: Bloomberg

US Biotech Says Drug Thwarted Muscle Loss in Wegovy Patients

8 months ago - By: Veru Inc.

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

9 months ago - By: Veru Inc.

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

10 months ago - By: Veru Inc.

Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders

a year ago - By: Veru Inc.

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek